Provectus Biopharma (NYSE:PVCT) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 1,651,635 shares, a growth of 1.8% from the June 30th total of 1,622,539 shares. Based on an average trading volume of 251,589 shares, the short-interest ratio is currently 6.6 days. Currently, 0.8% of the shares of the stock are short sold.
Provectus Biopharma (NYSE:PVCT) traded up 0.4434% during trading on Tuesday, reaching $0.2945. 94,733 shares of the company’s stock were exchanged. Provectus Biopharma has a 52 week low of $0.25 and a 52 week high of $0.70. The firm’s market capitalization is $62.68 million. The stock has a 50-day moving average price of $0.35 and a 200 day moving average price of $0.39.
Provectus Biopharma (NYSE:PVCT) last announced its earnings results on Tuesday, May 10th. The company reported ($0.04) earnings per share for the quarter. Equities research analysts forecast that Provectus Biopharma will post ($0.12) earnings per share for the current fiscal year.
Provectus Biopharmaceuticals, Inc is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer.
